Leukemia, Myeloid

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

CIML NK Cells With Venetoclax for AML

Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Allo HSCT Using RIC and PTCy for Hematological Diseases

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia

Breath Analysis for the Detection of Invasive Fungal Infections

Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia

Natural Killer Cell (CYNK-001) Infusions in Adults with AML

Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy

CD155 Expression in Acute Myeloid Leukemia

ELN 2022 in MENAFC ( Middle Eastern or North Coast of Africa ) Patients With Newly AML

Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG

CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia